We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+3.16%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$32.9M
AUM Growth
-$17.1M
Cap. Flow
-$11.9M
Cap. Flow %
-36.29%
Top 10 Hldgs %
99.98%
Holding
15
New
2
Increased
2
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$570K
2
LAB icon
Standard BioTools
LAB
+$274K
3
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$200K

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$8.93M
2
ASRT
Assertio
ASRT
+$4.05M

Sector Composition

Rank Sector Weight
1 Healthcare 84.88%
2 Miscellaneous 15.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYME
1
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$13.2M 40.26%
2,075,000
– –
GILD icon
2
Gilead Sciences
GILD
$185B
$5.37M 16.34%
75,000
– –
GILD icon
3
CALL
Gilead Sciences
GILD
$185B
$4.3M 13.07%
60,000
– –
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$3.12M 9.49%
1,000,000
+118,560
+13% +$570K
LAB icon
5
Standard BioTools
LAB
$253M
$2.42M 7.35%
410,500
+50,000
+14% +$274K
AMRN
6
Amarin Corp
AMRN
$299M
$1.8M 5.49%
22,500
– –
GSK icon
7
GSK
GSK
$101B
$1.77M 5.39%
40,000
– –
BIS icon
8
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$551K 1.68%
3,125
– –
SEEL
9
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$184K 0.56%
+1
New +$200K
MNKD icon
10
PUT
MannKind Corp
MNKD
$1.31B
$116K 0.35%
+50,000
New +$171K
FCSC
11
CALL
DELISTED
Fibrocell Science Inc.
FCSC
$6K 0.02%
2,000
– –
ASRT
12
DELISTED
Assertio
ASRT
– –
-11,667
Closed -$4.05M
ASRT
13
PUT
DELISTED
Assertio
ASRT
– –
-7,000
Closed -$2.43M
LAB icon
14
CALL
Standard BioTools
LAB
$253M
– –
-100,000
Closed -$504K
PFE icon
15
Pfizer
PFE
$160B
– –
-263,500
Closed -$8.93M

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Healthcare Value Capital held 15 positions worth $32.9M, down 34% from $50M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Healthcare Value Capital withdrew a net $11.9M in Q4 2017, closing 4 positions. Its most notable exit was Pfizer, an estimated $8.93M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital opened a new position in Seelos Therapeutics, Inc. Common Stock worth $184K.

  • Healthcare Value Capital's largest Q4 2017 buy was Seelos Therapeutics, Inc. Common Stock: 1 share worth $184K.
  • Healthcare Value Capital added most to Novelion Therapeutics Inc. Common Shares in Q4 2017, an estimated $570K increase.
  • Healthcare Value Capital fully exited Pfizer in Q4 2017, selling an estimated $8.93M.
  • Healthcare Value Capital's ten largest holdings make up 100% of its $32.9M portfolio in Q4 2017.
  • Healthcare Value Capital opened 2 new positions and closed 4 in Q4 2017.
  • Healthcare Value Capital's portfolio value fell 34% quarter-over-quarter to $32.9M.

Based on Healthcare Value Capital's 13F filing for Q4 2017, filed 23 Jan 2018.